News Archive

2020

June

Media Release / Jun 16, 2020

Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

Read More
Media Release / Jun 16, 2020

Novartis ILARIS® (canakinumab) receives FDA approval for new indication to treat Adult-Onset Still’s Disease (AOSD)

Read More
Media Release / Jun 15, 2020

Novartis manufactures and donates 27,000 units of hand sanitizer to New York State

Read More
Media Release / Jun 11, 2020

U.S. FDA approves updated Novartis BEOVU® label, to include additional safety information

Read More

May

Media Release / May 29, 2020

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

Read More
Media Release / May 27, 2020

Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)

Read More

April

Media Release / Apr 03, 2020

Novartis and the Novartis US Foundation establish USD 5 million US COVID-19 Community Response Fund

Read More

March

Media Release / Mar 28, 2020

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Read More
Media Release / Mar 28, 2020

Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Read More
Media Release / Mar 18, 2020

Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

Read More

Related Links